Inari Medical Announces Chief Financial Officer Retirement and Succession Plan
Inari Medical (NASDAQ: NARI) has announced a succession plan for its Chief Financial Officer position. Mitch Hill, the current CFO, will retire effective October 1, 2024, after serving in the role since 2019. He will be succeeded by Kevin Strange, who is currently the SVP of Finance, Accounting, Strategy and Business Development at Inari.
Strange joined Inari in 2020 and has been leading the company's day-to-day financial and accounting operations since 2023. He brings over 15 years of experience in financial and business development leadership roles within the medical device industry. CEO Drew Hykes expressed confidence in Strange's ability to lead Inari's finance and accounting organization into its next growth phase.
Inari Medical (NASDAQ: NARI) ha annunciato un piano di successione per la posizione di Chief Financial Officer. Mitch Hill, l'attuale CFO, andrà in pensione a partire dal 1 ottobre 2024, dopo aver ricoperto il ruolo dal 2019. Sarà succeduto da Kevin Strange, attuale SVP Finanza, Contabilità, Strategia e Sviluppo Aziendale di Inari.
Strange è entrato in Inari nel 2020 e ha guidato le operazioni finanziarie e contabili quotidiane dell'azienda dal 2023. Porta con sé oltre 15 anni di esperienza in ruolo di leadership nel settore della finanza e dello sviluppo commerciale nell’industria dei dispositivi medici. Il CEO Drew Hykes ha espresso fiducia nella capacità di Strange di guidare l'organizzazione finanziaria e contabile di Inari verso la prossima fase di crescita.
Inari Medical (NASDAQ: NARI) ha anunciado un plan de sucesión para el puesto de Director Financiero. Mitch Hill, el actual CFO, se retirará a partir del 1 de octubre de 2024, después de haber ocupado el cargo desde 2019. Será sucedido por Kevin Strange, que actualmente es SVP de Finanzas, Contabilidad, Estrategia y Desarrollo Comercial en Inari.
Strange se unió a Inari en 2020 y ha estado liderando las operaciones financieras y contables diarias de la empresa desde 2023. Aporta más de 15 años de experiencia en roles de liderazgo en finanzas y desarrollo comercial dentro de la industria de dispositivos médicos. El CEO Drew Hykes expresó confianza en la capacidad de Strange para dirigir la organización de finanzas y contabilidad de Inari hacia su próxima fase de crecimiento.
이나라 메디컬(NASDAQ: NARI)이 최고재무책임자(CFO) 직위에 대한 후계 계획을 발표했습니다. 현재 CFO인 Mitch Hill은 2019년부터 역할을 해왔으며 2024년 10월 1일 부로 은퇴할 예정입니다. 그는 현재 재무, 회계, 전략 및 사업 개발의 SVP인 Kevin Strange가 후임자로 들어섭니다.
Strange는 2020년에 이나라에 합류했으며 2023년부터 회사의 일상적인 재무 및 회계 운영을 이끌고 있습니다. 그는 의료 기기 산업에서 재무 및 사업 개발 리더십 역할에 15년 이상의 경험을 가지고 있습니다. CEO Drew Hykes는 Strange가 이나라의 재무 및 회계 조직을 다음 성장 단계로 이끌 수 있을 것이라 확신하고 있습니다.
Inari Medical (NASDAQ: NARI) a annoncé un plan de succession pour son poste de directeur financier (CFO). Mitch Hill, l'actuel CFO, prendra sa retraite à compter du 1er octobre 2024, après avoir occupé ce poste depuis 2019. Il sera remplacé par Kevin Strange, qui est actuellement SVP Finances, Comptabilité, Stratégie et Développement Commercial chez Inari.
Strange a rejoint Inari en 2020 et dirige les opérations financières et comptables quotidiennes de l'entreprise depuis 2023. Il apporte plus de 15 ans d'expérience dans des postes de leadership en finance et en développement commercial dans l'industrie des dispositifs médicaux. Le PDG Drew Hykes a exprimé sa confiance dans la capacité de Strange à diriger l'organisation financière et comptable d'Inari vers sa prochaine phase de croissance.
Inari Medical (NASDAQ: NARI) hat einen Nachfolgeplan für die Position des Chief Financial Officer (CFO) angekündigt. Mitch Hill, der aktuelle CFO, wird am 1. Oktober 2024 in den Ruhestand gehen, nachdem er seit 2019 im Amt ist. Ihm wird Kevin Strange nachfolgen, der derzeit Senior Vice President für Finanzen, Buchhaltung, Strategie und Geschäftsentwicklung bei Inari ist.
Strange trat 2020 in Inari ein und leitet seit 2023 die täglichen Finanz- und Buchhaltungsoperationen des Unternehmens. Er bringt über 15 Jahre Erfahrung in Führungspositionen im Finanz- und Geschäftsentwicklungsbereich in der Medizintechnik mit. CEO Drew Hykes äußerte Vertrauen in Strange's Fähigkeit, die Finanz- und Buchhaltungsorganisation von Inari in die nächste Wachstumsphase zu führen.
- Planned smooth transition of CFO role indicates good succession planning
- New CFO Kevin Strange has been with the company since 2020, ensuring continuity
- Strange brings over 15 years of experience in financial and business development leadership in the medical device industry
- None.
Mitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024
IRVINE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that Mitch Hill, Chief Financial Officer, will retire effective October 1, 2024 and will be succeeded by Kevin Strange, Inari’s current SVP, Finance, Accounting, Strategy and Business Development. Mr. Hill has served as the CFO since 2019, and prior to that in various senior financial roles spanning over four decades.
Mr. Strange joined Inari in 2020 as VP, Strategy and Business Development. Since 2023 he has served as the SVP, Finance, Accounting, Strategy and Business Development leading Inari’s day to day financial and accounting operations. Prior to joining Inari, he has over 15 years of experience in various financial and business development leadership roles within the medical device space.
“Over the last five years, Mitch helped build and scale a robust financial, operating, and technology foundation for Inari,” said Drew Hykes, Inari CEO. “He also led our IPO in May 2020 and helped us identify and develop Kevin Strange as his successor. We thank Mitch for his myriad contributions to Inari and his unwavering commitment to our patients. Looking ahead, I couldn’t be more confident in the leadership Kevin will provide as Inari’s next CFO. In addition to being a highly experienced financial executive, Kevin is deeply passionate about Inari’s mission. He is uniquely qualified to lead our finance and accounting organization into the next phase of growth. I expect a seamless transition of the CFO role from Mitch to Kevin.”
“I am excited and honored to be named as Inari’s next CFO,” said Kevin Strange. “Since I joined in 2020, the company has experienced immense growth and change. What has been constant is our steadfast commitment to our mission to serve patients, take care of each other and pursue big ideas. Like Mitch, I am deeply committed to these ideals and look forward to serving Inari through its next phase of growth.”
About Kevin Strange
Mr. Strange is a proven medical device executive with broad functional and sector experience. Since 2023, he has served as SVP, Finance, Accounting, Strategy and Business Development of Inari Medical leading its financial, accounting and business development functions. From 2020 to 2023, he served as Inari’s VP, Strategy and Business Development, leading the Company’s first acquisition in October 2023. Prior to Inari, Mr. Strange was the Director of Business Development for the Peripheral Interventions division of Boston Scientific. Prior to that, Mr. Strange spent five years as an equity research analyst at Wells Fargo Securities and Bank of America Merrill Lynch covering the MedTech sector. Mr. Strange started his career in medical devices in the Cardiac Rhythm Management division of Medtronic. Mr. Strange holds a BS in Biology from Davidson College and an MBA from New York University’s Stern School of Business.
Second Quarter 2024 Financial Results
In a separate press release issued today, the Company announced its financial results for its second quarter 2024 ended June 30, 2024. The Company will host a conference call with investors and analysts today at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to review its financial results.
About Inari Medical, Inc.
Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and four other targeted disease states. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram.
Investor Contact:
Marissa Bych
Gilmartin Group LLC
IR@inarimedical.com
FAQ
When will Mitch Hill retire as CFO of Inari Medical (NARI)?
Who will succeed Mitch Hill as CFO of Inari Medical (NARI)?
When did Kevin Strange join Inari Medical (NARI)?
How long has Mitch Hill served as CFO of Inari Medical (NARI)?
